FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Machinatan	D C	20540
Washington,	D.C.	20049

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Kovacs Shane William Charles</u>					2. Issuer Name and Ticker or Trading Symbol Olema Pharmaceuticals, Inc. [ OLMA ]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner					
(Last)	,	irst) RMACEUTICAI	(Middle) LS, INC.		3. Date of Earliest Transaction (Month/Day/Year) 02/01/2024							X Officer (give title Other (specify below)  CH. OPERATING & FINANCIAL OF				
780 BRANNAN ST				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)					Line)	6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) SAN FRANCI	sco C.	A	94103								) 		ed by More		ting Person One Reporti	ng
(City)	(S	tate)	(Zip)	_   F	Rule 10b5-1(c) Transaction Indication  Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.											
			ble I - Non-D						_							
Date			Transaction te onth/Day/	Execution Date,		Code (Instr.		ed (A) or str. 3, 4 and 5	5. Amour 4 and 5) Securitie Beneficia Owned F Reported		Form: (D) or	m: Direct I or Indirect I nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
						Code V	Amount	(A) o (D)	r Price	Transacti (Instr. 3 a				(mstr. 4)		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)  (Month/Day/Year)  3. Deemed Execution Date if any (Month/Day/Year)	Code (Instr.		Derivative I		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)			
Stock Option (Right to Buy)	\$15.25	02/01/2024		A		304,500		(1)	01/31/2034	Common Stock	304,500	\$0	304,50	00	D	

## Explanation of Responses:

1. 25% of the shares subject to the option vest on February 1, 2025 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

/s/ Shane Kovacs

02/05/2024

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.